Browsing: 3.05B

Listen to this article Johnson & Johnson finalized its $3.05 billion acquisition of clinical-stage biotech Halda Therapeutics OpCo. Inc. In a Dec. 29 press release announcing…

Listen to this article The basics: J&J to acquire Halda Therapeutics in $3.05B oncology-focused deal Acquisition adds prostate cancer therapy HLD-0915 and early-stage tumor candidates Strengthens…